Related Experiment Video

Updated: Sep 19, 2025

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

7.7K

The role of miR-429 in cancer: From biogenesis, signaling pathways, interactions with long non-coding RNAs, and

Ensiyeh Bahadoran1, Abouzar Babaei2, Reza Ranji3

  • 1Cellular and Molecular Research Center, Research Institute for Prevention of Non, Communicable Disease, Qazvin University of Medical Sciences, Qazvin, Iran.

Critical Reviews in Oncology/Hematology
|June 6, 2025
PubMed

Insights

MicroRNAs (miRNAs), specifically miR-429, are key regulators in cancer, impacting cell processes and metastasis. This review explores miR-429's role in various cancers and its potential as a diagnostic and therapeutic target.

Area of Science:

  • Molecular Biology
  • Genetics
  • Oncology

Background:

  • MicroRNAs (miRNAs) are crucial gene expression regulators in cancer biology.
  • miR-429, part of the miR-200 family, affects cell migration, metastasis, apoptosis, and proliferation.
  • Understanding miR-429's molecular mechanisms is vital for cancer research.

Purpose of the Study:

  • To review the biogenesis, regulation, and signaling pathways of miR-429.
  • To investigate miR-429 interactions with long non-coding RNAs (lncRNAs) and other networks in tumorigenesis.
  • To explore the clinical relevance of miR-429 in various cancers.

Main Methods:

  • Literature review of miR-429's role in cancer.
  • Analysis of miR-429 expression patterns in different malignancies.
  • Examination of miR-429's interactions with molecular networks.

Main Results:

  • miR-429 exhibits diverse expression patterns across renal cell carcinoma, esophageal cancer, breast cancer, lung cancer, and glioblastoma.
  • miR-429 plays a dual role in tumorigenesis and metastasis.
  • Complex mechanisms of miR-429 action identified in various cancers.

Conclusions:

  • miR-429 is a significant factor in cancer development and progression.
  • miR-429 shows potential as a biomarker for cancer diagnosis and prognosis.
  • miR-429 presents promising therapeutic implications for targeted cancer therapy.
Keywords:
CancerCancer diagnosisMiR-429Signaling pathwaysTherapeutic application

More Related Videos

miRNA Expression Analyses in Prostate Cancer Clinical Tissues11:29

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

10.9K
An In Vitro Protocol for Evaluating MicroRNA Levels, Functions, and Associated Target Genes in Tumor Cells09:45

An In Vitro Protocol for Evaluating MicroRNA Levels, Functions, and Associated Target Genes in Tumor Cells

Published on: May 21, 2019

8.5K

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.0K
Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.3K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.0K